TrialGynecologic oncology2025

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

Bradley R Corr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.